Chardan raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $46 from $45 and keeps a Buy rating on the shares. The company presented initial data on RP-A601 that demonstrated signals of increased cardiac PKP2 expression, together with improvement in arrhythmia burden, heart function, and quality of life, the analyst tells investors in a research note. The firm believes the data collectively signal RP-A601 is driving some form of benefits.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Promising Developments and Strategic Advancements Make Rocket Pharmaceuticals a Compelling Buy
- Promising Clinical Data and Potential FDA Pathway Justify Buy Rating for Rocket Pharmaceuticals
- Promising Potential of Rocket Pharmaceuticals’ RP-A601: Buy Rating Justified by Encouraging Phase 1 Results and Advancements
- Lexeo Therapeutics price target lowered to $15 from $23 at H.C. Wainwright
- Promising Potential of Rocket Pharmaceuticals’ RP-A601: Buy Rating Supported by Positive Phase I Data and Future Prospects